LAUSR

World Psychiatry 20:3 October 2021 concussions, airborne allergen and pollutant exposure, as well as psychosocial stressors. Future research goals are to examine how to best monitor, prevent and treat psychiatric, behavioral and cognitive consequences of COVID-19. For clinicians treating depression in patients with SARS-CoV-2 infection, a thorough history and clinical examination are paramount. There is evidence that immune-inflammatory dysregulation is limiting the efficacy of antidepressants, as high plasma levels of CRP and interleukins have been found to be predictors of poor treatment response. Consequently, whether antidepressants are effective in treating COVID-19-related depression deserves specific confirmation. In the meantime, we can assume that any major advances in vaccines and antiviral treatments targeting SARS-CoV-2, as well as immune targeted therapies (such as anti-cytokines and cytokine receptor blockers), will not only prevent severe illness but also benefit the brain and mental health.